J07BN
Covid-19 vaccines
Наименование на групата: WHO Collaborating Centre for Drug Statistics Methodology
Подгрупи
ATC класификацията е дърво. Тази категория се разделя на 2 подгрупи.
Лекарствени продукти в тази категория
6 продукта в тази категория и подгрупите ѝ.
| Търговско име | Концентрация |
|---|---|
| BIMERVAX | --¹ One dose (0.5 mL) contains: 40 micrograms of selvacovatein adjuvanted with SQBA (EU/1/22/1709/001-004). Selvacovatein is a SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351 and B.1.1.7 strains) produced by recombinant DNA technology using a plasmid expression vector in a CHO cell line. SQBA adjuvant containing per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections. |
| COMIRNATY | -¹⁵ COMIRNATY JN.1 30 micrograms/dose dispersion for injection (EU/1/20/1528/028-031, EU/1/20/1528/043): 1 dose (0.3 mL) contains 30 micrograms of bretovameran, COVID-19 mRNA Vaccine (nucleoside modified, embedded in lipid nanoparticles). Bretovameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (Omicron JN.1). |
| Kostaive | --¹ After reconstitution with 10 mL of sterile 0.9% Sodium Chloride Injection, one dose (0.5 mL) contains 5 micrograms of Zapomeran, a COVID-19 mRNA (encapsulated in lipid nanoparticles). Zapomeran is a single-stranded, 5'-capped messenger RNA (mRNA) replicon (self-amplifying mRNA), produced using a cell-free in vitro transcription from the corresponding DNA templates encoding a replicase and the spike glycoprotein of the G clade D614G variant of SARS-CoV-2. |
| mNEXSPIKE | --¹ One dose (0.2 mL) contains 10 micrograms of SARS-CoV-2 mRNA. mNEXSPIKE is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding the N-terminal domain and receptor-binding domain of the viral spike (S) protein of SARS-CoV-2 (XBB.1.5). |
| Nuvaxovid | --¹ One dose (0.5 ml) contains 5 µg of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. Adjuvant Matrix-M containing per 0.5 mL dose: Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract. * produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the Spodoptera frugiperda species. |
| Spikevax | --⁶ One dose (0.5 mL) contains 50 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). One dose (0.25 mL) contains 25 micrograms of SARS-CoV-2 JN.1 mRNA, a COVID-19 mRNA Vaccine (nucleoside modified) (embedded in lipid nanoparticles). SARS-CoV-2 JN.1 mRNA is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2 (JN.1). |